Cabtreo, a combination of clindamycin phosphate, adapalene, and benzoyl peroxide, was FDA-approved on October 20, 2023.

Eli Lilly currently holds the throne as the world's most valuable pharmaceutical company by market capitalization.

Sitagliptin is approved by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes mellitus in adults. This approval was first granted on October 18, 2006.

ALX Oncology's Phase 2 ASPEN-06 Trial Shows Evorpacept Enhances Tumor Response in HER2-Positive Gastric Cancer Patients.

etrasimod (Velsipity) is FDA approved. The FDA granted its approval on October 12, 2023. This approval allows for the use of etrasimod in the treatment of adults with moderately to severely active ulcerative colitis.

Aug 7th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Momelotinib, marketed under the brand name Ojjaara, was approved by the FDA on September 15, 2023.

Instil Bio and ImmuneOnco reveal partnership for IMM2510, a leading PD-L1xVEGF bispecific antibody, and IMM27M, an advanced anti-CTLA-4 antibody.

Motixafortide, marketed under the brand name Aphexda, was approved by the FDA on September 8, 2023.

Lilly's tirzepatide shows positive results in phase 3 trial for obese adults with heart failure and preserved ejection fraction.

Pozelimab, marketed under the brand name Veopoz, is FDA approved.

REGENXBIO Inc. announced fresh, encouraging interim results on safety and efficacy from the Phase I/II AFFINITY DUCHENNE trial of RGX-202 in Duchenne muscular dystrophy patients aged 1 to 11 years.